Lyophilized Polymeric Wafer for Rapid Oral Dissolution

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing pharmaceutical dosage forms, particularly wafers, face challenges in rapid disintegration and dissolution, leading to ineffective delivery of active pharmaceutical ingredients (APIs) through mucosal membranes, and they are often fragile, requiring specialized packaging and having limited stability and patient compliance issues.

Innovation Solution

A pharmaceutical dosage form comprising a soluble matrix forming polymer like hydroxypropyl cellulose, an ester containing derivative of an acrylic polymer such as sodium polyacrylate, an anti-collapsing agent like diglycine, and a filler substance like maltodextrin, which forms a robust and rapidly dissolving wafer structure, potentially incorporating a taste masking agent like hydroxypropyl-beta-cyclodextrin (HPβCD) for enhanced API delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If lyophilized polymeric matrices are used for rapid dissolution, then dissolution speed is improved, but mechanical strength deteriorates causing fragility and handling difficulty

Engineering Contradiction:

Improvedissolution speedVSAvoidmechanical strength

Core Design Contradiction:

SpeedVSStrength

Solution Approach 1:

The patent uses a composite polymeric matrix combining hydroxypropyl cellulose (water-soluble polymer) with maltodextrin (filler substance) and diglycine (anti-collapsing agent). This composite structure provides both rapid dissolution properties from the hydrophilic polymer and mechanical robustness from the filler and anti-collapsing agents, resolving the contradiction between fast dissolution and structural strength.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies the physical and chemical parameters of the matrix by controlling the ratio of polymer to filler substances, adjusting molecular weight, and optimizing lyophilization parameters. These parameter changes enable the matrix to achieve both rapid disintegration and adequate mechanical strength for handling without specialized packaging.

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If polymeric matrices are made robust for easy handling, then ease of operation is improved, but dissolution speed may deteriorate

Engineering Contradiction:

Improveease of handlingVSAvoiddissolution speed

Core Design Contradiction:

Ease of operationVSSpeed

Solution Approach 1:

The composite matrix uses hydroxypropyl cellulose as the continuous phase for rapid dissolution, while incorporating maltodextrin and diglycine as dispersed phases that provide structural support. This composite architecture allows the matrix to be handled easily while maintaining fast dissolution characteristics when contacted with aqueous media.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent creates local quality differentiation within the matrix where the polymeric components provide dissolution pathways and the filler substances provide structural framework. This spatial differentiation of functions allows simultaneous achievement of robustness and rapid dissolution.

Inventive Principle:

Principle #3Local quality

3Ease of manufacture

If conventional OSD forms are used for API delivery, then manufacturing simplicity is improved, but bioavailability deteriorates due to gastric passage issues

Engineering Contradiction:

Improvemanufacturing simplicityVSAvoidbioavailability

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent replaces the conventional oral solid dosage form (tablet/capsule) that relies on gastric dissolution with a lyophilized polymeric wafer that dissolves rapidly in the oral cavity through salivary moisture. This substitution of the dissolution environment (from gastric to oral) maintains manufacturing simplicity while dramatically improving bioavailability for APIs with poor gastric solubility.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dosage form achieves ultra-fast disintegration and dissolution, ensuring effective API delivery, improved patient compliance due to smooth texture and non-gritty mouth feel, and stability without the need for special packaging, while maintaining robustness and ease of handling.

Implementation Method 1

the polymers and/or excipients used to manufacture the wafer must be soluble at physiological temperature (about 37°C) without the aid of heating or stirring

Methodology Applied

Scientific EffectSolvation: Solvation

Implementation Method 2

rapid disintegration and dissolution characteristics in use

Methodology Applied

Scientific EffectDissolution:

Data Source

PatentEP2895147B1Rapidly dissolving pharmaceutical composition

Publication Date: 2019.06.26 UNIVERSITY OF THE WITWATERSRAND

Figure 1
Figure 2a~2c
Figure 3a~3c

AI summary

The present invention relates to a pharmaceutical dosage form which may comprise carbamoyl glycinated chitosan, and particularly it relates to a pharmaceutical dosage form comprising the novel polymer in a lyophilized polymeric wafer form which shows rapid disintegration and dissolution characteristics in use.